Literature DB >> 12879322

The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.

Zhenhua Lin1, Hankyeom Kim, Hongseok Park, Youngsik Kim, Jun Cheon, Insun Kim.   

Abstract

The bcl-2 proto-oncogene plays a key role in cell longevity by preventing apoptosis. Bcl-2 is important in developing and maintaining the normal function of lymphoid and epithelial tissues. The bcl-6 protein is a 96 kDa nuclear protein selectively expressed in mature B cells within normal germinal centers as well as in their transformed counterparts in diffuse large B cell lymphoma. Recently, the bcl-6 protein has also been reported to be expressed in normal skin and epidermal neoplasms. In this study, 47 cases of transitional cell carcinomas (TCCs) were immunohistochemically studied for bcl-2 and bcl-6 protein expression. The results showed that bcl-2 was expressed only on basal layer cells, whereas bcl-6 expression was restricted to the superficial layers in the normal transitional epithelium. Von Brunn's nests showed strong immunostaining to bcl-2, but were negative to bcl-6. Among 47 TCCs, 15 (32.6%) and 29 (61.7%) cases were positive for bcl-2 and bcl-6, respectively. Compared with the normal transitional epithelium, the expression of bcl-2 was significantly decreased, whereas bcl-6 expression was significantly increased in TCCs. Additionally, the strong expression of bcl-6 had a positive correlation with the histopathologic grade of TCC. In conclusion, bcl-2 and bcl-6 proteins may play a role in the pathogenesis of TCCs, and bcl-6 expression reflects histopathologic grade.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879322     DOI: 10.1007/s00240-003-0324-3

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  21 in total

1.  Expression of bcl-6 protein in normal skin and epidermal neoplasms.

Authors:  N Kanazawa; M Moriyama; T Onizuka; K Sugawara; S Mori
Journal:  Pathol Int       Date:  1997-09       Impact factor: 2.534

2.  Expression of bcl-2 protein in gastric carcinoma and its significance.

Authors:  Hai-Feng Liu; Wei-Wen Liu; Dian-Chun Fang; Rong-Pu Men
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

3.  Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix.

Authors:  E Giarnieri; R Mancini; T Pisani; M Alderisio; A Vecchione
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

4.  Transcriptional repression by the proto-oncogene BCL-6.

Authors:  V L Seyfert; D Allman; Y He; L M Staudt
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

5.  Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.

Authors:  B H Ye; F Lista; F Lo Coco; D M Knowles; K Offit; R S Chaganti; R Dalla-Favera
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

6.  The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.

Authors:  L Nakopoulou; C Vourlakou; A Zervas; A Tzonou; H Gakiopoulou; M A Dimopoulos
Journal:  Hum Pathol       Date:  1998-02       Impact factor: 3.466

7.  Expression of bcl-2 and bcl-X in bladder cancer.

Authors:  E J Kirsh; D A Baunoch; W M Stadler
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

8.  Maturation of the immune response in germinal centers.

Authors:  C Berek; A Berger; M Apel
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

9.  Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry.

Authors:  S Eissa; L S Seada
Journal:  Clin Chem       Date:  1998-07       Impact factor: 8.327

10.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

Authors:  G Fontanini; S Vignati; D Bigini; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Bevilacqua
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  7 in total

1.  Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and bcl-2.

Authors:  Zahra Amirghofran; Ahmad Monabati; Abdolaziz Khezri; Zahra Malek-Hosseini
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

2.  Rac1 signaling modulates BCL-6-mediated repression of gene transcription.

Authors:  Patrícia Barros; Peter Jordan; Paulo Matos
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

3.  FOXO responses to Porphyromonas gingivalis in epithelial cells.

Authors:  Qian Wang; Maryta Sztukowska; Akintunde Ojo; David A Scott; Huizhi Wang; Richard J Lamont
Journal:  Cell Microbiol       Date:  2015-05-29       Impact factor: 3.715

4.  Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters.

Authors:  Patrícia Barros; Eric W-F Lam; Peter Jordan; Paulo Matos
Journal:  Nucleic Acids Res       Date:  2012-06-20       Impact factor: 16.971

5.  BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.

Authors:  Peir-In Liang; Chien-Feng Li; Li-Tzong Chen; Ding-Ping Sun; Tzu-Ju Chen; Chung-Hsi Hsing; Han-Ping Hsu; Ching-Yih Lin
Journal:  Tumour Biol       Date:  2013-10-11

6.  Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma.

Authors:  Islem Ben Bahria-Sediki; Nadhir Yousfi; Catherine Paul; Mohamed Chebil; Mohamed Cherif; Rachida Zermani; Amel Ben Ammar El Gaaied; Ali Bettaieb
Journal:  J Transl Med       Date:  2016-05-30       Impact factor: 5.531

7.  Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.

Authors:  Wen-Ren Wu; Jen-Tai Lin; Cheng-Tang Pan; Ti-Chun Chan; Chen-Liang Liu; Wen-Jeng Wu; Jim Jinn-Chyuan Sheu; Bi-Wen Yeh; Steven K Huang; Jheng-Yan Jhung; Meng-Shin Hsiao; Chien-Feng Li; Yow-Ling Shiue
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.